Jump to Main Content

FDA Alerts

FDA Approved Betrixaban (BEVYXXA, Portola) for the Prophylaxis of Venous Thromboembolism (VTE) in Adult Patients

The U.S. Food and Drug Administration approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.